X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (368) 368
oncology (364) 364
female (301) 301
index medicus (295) 295
chemotherapy (234) 234
dose-dense (218) 218
middle aged (197) 197
breast neoplasms - drug therapy (180) 180
breast cancer (175) 175
adult (171) 171
aged (164) 164
cancer (160) 160
antineoplastic combined chemotherapy protocols - therapeutic use (159) 159
paclitaxel (135) 135
dose-dense chemotherapy (129) 129
treatment outcome (125) 125
cyclophosphamide (115) 115
antineoplastic combined chemotherapy protocols - adverse effects (101) 101
drug administration schedule (92) 92
paclitaxel - administration & dosage (91) 91
antineoplastic combined chemotherapy protocols - administration & dosage (89) 89
randomized-trial (89) 89
breast neoplasms - pathology (87) 87
doxorubicin (83) 83
chemotherapy, adjuvant (82) 82
therapy (81) 81
adjuvant chemotherapy (80) 80
dose-response relationship, drug (78) 78
trial (78) 78
male (77) 77
neoadjuvant chemotherapy (73) 73
disease-free survival (72) 72
medicine & public health (70) 70
adjuvant treatment (69) 69
docetaxel (68) 68
prognosis (67) 67
care and treatment (66) 66
cyclophosphamide - administration & dosage (62) 62
epirubicin (60) 60
survival (58) 58
anthracyclines (57) 57
women (57) 57
carboplatin (56) 56
hematology, oncology and palliative medicine (53) 53
phase-iii trial (53) 53
research (53) 53
drug therapy (52) 52
neoplasm staging (51) 51
obstetrics & gynecology (50) 50
open-label (49) 49
ovarian cancer (49) 49
clinical trials (48) 48
taxoids - administration & dosage (48) 48
combination chemotherapy (47) 47
doxorubicin - administration & dosage (47) 47
antineoplastic agents - therapeutic use (46) 46
neoadjuvant therapy (46) 46
filgrastim (45) 45
colony-stimulating factor (43) 43
survival analysis (42) 42
bevacizumab (41) 41
analysis (40) 40
carboplatin - administration & dosage (40) 40
hematology (40) 40
paclitaxel - adverse effects (39) 39
ovarian neoplasms - drug therapy (38) 38
aged, 80 and over (37) 37
cisplatin (37) 37
randomized controlled trials as topic (37) 37
antineoplastic agents - administration & dosage (36) 36
breast-cancer (36) 36
health aspects (36) 36
retrospective studies (36) 36
trastuzumab (36) 36
carcinoma (35) 35
epirubicin - administration & dosage (34) 34
survival rate (34) 34
pharmacology & pharmacy (33) 33
radiotherapy (33) 33
risk factors (33) 33
phase-ii trial (32) 32
temozolomide (32) 32
toxicity (32) 32
follow-up studies (31) 31
granulocyte colony-stimulating factor - administration & dosage (31) 31
phase-ii (31) 31
granulocyte colony-stimulating factor - therapeutic use (30) 30
polyethylene glycols (30) 30
review (30) 30
follow-up (29) 29
phase-iii (29) 29
antineoplastic agents - adverse effects (28) 28
breast neoplasms - mortality (28) 28
breast neoplasms - surgery (28) 28
cancer therapies (28) 28
elderly-patients (28) 28
fluorouracil (28) 28
pathological complete response (28) 28
young adult (28) 28
cancer patients (27) 27
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (511) 511
German (12) 12
French (4) 4
Korean (4) 4
Japanese (3) 3
Russian (2) 2
Czech (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


LANCET ONCOLOGY, ISSN 1470-2045, 07/2017, Volume 18, Issue 7, pp. 929 - 945
Background Adjuvant chemotherapy for early breast cancer has improved outcomes but causes toxicity. The UK TACT2 trial used a 2 x 2 factorial design to test... 
WOMEN | ONCOLOGY | DOSE-DENSE | DOCETAXEL | CHEMOTHERAPY | PACLITAXEL
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 10/2017, Volume 15, Issue 10, pp. 1240 - 1267
This selection from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Bladder Cancer focuses on systemic therapy for muscle-invasive... 
PHASE-III TRIAL | ADJUVANT CHEMOTHERAPY | GEMCITABINE PLUS CISPLATIN | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | URINARY-BLADDER | TRANSITIONAL-CELL CARCINOMA | LONG-TERM OUTCOMES | RADICAL CYSTECTOMY | DOSE-DENSE METHOTREXATE | METASTATIC UROTHELIAL CARCINOMA
Journal Article
Oncotarget, ISSN 1949-2553, 06/2018, Volume 9, Issue 44, pp. 27380 - 27396
Dose-dense chemotherapy is one of the treatments of choice for neoadjuvant therapy in breast cancer (BC). Activating mutations in gene predict worse response... 
Real life | Dose-dense | Neaodjuvant | PIK3CA
Journal Article
ONCOLOGY-NEW YORK, ISSN 0890-9091, 02/2018, Volume 32, Issue 2, pp. 75 - 75
Journal Article
European Journal of Obstetrics & Gynecology and Reproductive Biology, ISSN 0301-2115, 01/2020, Volume 244, pp. 101 - 105
Hyperthermic intraperitoneal chemotherapy (HIPEC), intraperitoneal chemotherapy (IP) and dose-dense (DD) chemotherapy have been employed with varying success... 
HIPEC | Survival | Intraperitoneal chemotherapy | Dose-dense chemotherapy | Ovarian cancer
Journal Article
GYNECOLOGIC ONCOLOGY, ISSN 0090-8258, 05/2019, Volume 153, Issue 2, pp. 376 - 380
Objectives. A recent randomized controlled trial demonstrated an overall survival benefit to the addition of hyperthermic intraperitoneal chemotherapy (HIPEC)... 
CYTOREDUCTIVE SURGERY | HIPEC | ONCOLOGY | PERITONEAL CARCINOMATOSIS | DOSE-DENSE | Cost-effectiveness | INTRAVENOUS CHEMOTHERAPY | ECONOMIC-ANALYSIS | Ovarian cancer | OBSTETRICS & GYNECOLOGY
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10087, pp. 2430 - 2442
Summary Triple-negative breast cancer is a heterogeneous disease and specific therapies have not been available for a long time. Therefore, conventional... 
Internal Medicine | TUMOR-INFILTRATING LYMPHOCYTES | BASAL-LIKE | MEDICINE, GENERAL & INTERNAL | ADENOID CYSTIC CARCINOMAS | NEOADJUVANT CHEMOTHERAPY | GENE-EXPRESSION | PHASE-II | SYNTHETIC LETHALITY | OPEN-LABEL | ADJUVANT BEVACIZUMAB | DOSE-DENSE DOXORUBICIN | Humans | Gene Expression Profiling - methods | Antineoplastic Agents - therapeutic use | Triple Negative Breast Neoplasms - drug therapy | Triple Negative Breast Neoplasms - immunology | Triple Negative Breast Neoplasms - genetics | Neoadjuvant Therapy - methods | Biomarkers, Tumor - metabolism | Female | Mutation | Genomics - methods | Ubiquitin-Protein Ligases - genetics | BRCA2 Protein - genetics | Molecular Targeted Therapy - methods | Lymphocytes, Tumor-Infiltrating - immunology | Medical research | Chemotherapy | RNA | Analysis | Stem cells | Medicine, Experimental | Breast cancer | Hormones, Sex | Angiogenesis inhibitors | Cancer | Androgens | Research institutes | Intervention | Therapy | State of the art | Mesenchyme | Androgen receptors | Homologous recombination | DNA damage | Medical services | Series (mathematics) | Clinical trials | Homology | Oncology | mRNA | Biology | Metastasis | Cancer therapies | Subgroups | Receptors | Alterations | Immunology | Signatures | Damage | Deoxyribonucleic acid--DNA | BRCA2 protein | BRCA1 protein | Markers | Gene expression | Biological activity | Inhibitors | Immune checkpoint | Breast | Tumors
Journal Article
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, ISSN 1540-1405, 10/2016, Volume 14, Issue 10, pp. 1213 - 1224
These NCCN Guidelines Insights discuss the major recent updates to the NCCN Guidelines for Bladder Cancer based on the review of the evidence in conjunction... 
PHASE-III TRIAL | BACILLUS-CALMETTE-GUERIN | GEMCITABINE PLUS CISPLATIN | GROUP RANDOMIZED PHASE-3 | NEOADJUVANT CHEMOTHERAPY | ONCOLOGY | TRANSITIONAL-CELL CARCINOMA | HIGH-RISK TA | DOSE-DENSE METHOTREXATE | T1 PAPILLARY CARCINOMA | ADVANCED UROTHELIAL CANCER
Journal Article
Nutrition and Cancer, ISSN 0163-5581, 2018, Volume 70, Issue 8, pp. 1339 - 1347
Objective: O-6-methylguanine (O6-meG) DNA-methyltransferase (MGMT) is a main regulator of temozolomide (TMZ) resistance in glioblastomas. Some MGMT inhibitors... 
DOSE-DENSE TEMOZOLOMIDE | TEA POLYPHENOLS | REPAIR | NUTRITION & DIETETICS | ONCOLOGY | MGMT | IN-VIVO | DOWN-REGULATION | CHEMISTRY | RADIOTHERAPY | CANCER | O-6-BENZYLGUANINE
Journal Article
Carcinogenesis, ISSN 0143-3334, 03/2019, Volume 40, Issue 1, pp. 2 - 14
Abstract Glioblastoma (GBM) is amongst the most aggressive brain tumors with a dismal prognosis. Despite significant advances in the current multimodality... 
LACTATE-DEHYDROGENASE | DOSE-DENSE TEMOZOLOMIDE | IN-VITRO | ONCOLOGY | DICHLOROACETATE DCA | ADULT HUMAN BRAIN | SELF-RENEWAL | PHASE-II | MULTIDRUG-RESISTANCE | ERBB FAMILY BLOCKER | TUMOR-INITIATING CELLS | Index Medicus
Journal Article
BREAST JOURNAL, ISSN 1075-122X, 07/2018, Volume 24, Issue 4, pp. 610 - 614
Many studies have sought to optimize the dosing schedule of adjuvant chemotherapy in early-stage breast cancer. Here, we assessed the use of continuous... 
TRIAL | adjuvant chemotherapy | metronomic | ONCOLOGY | DOSE-DENSE | nab-paclitaxel | CHEMOTHERAPY | OBSTETRICS & GYNECOLOGY
Journal Article
The Oncologist, ISSN 1083-7159, 05/2019, Volume 24, Issue 5, pp. 603 - 611
Background Neoadjuvant treatment is increasingly one of the preferred therapeutic options for early breast cancer and may have some unique outcomes, such as... 
HER therapy | Chemotherapy | Cost analysis | Surgery | Hormonal therapy | NAB-PACLITAXEL | ENDOCRINE THERAPY | RANDOMIZED-TRIAL | OPEN-LABEL | SYSTEMIC THERAPY | PLUS TRASTUZUMAB | PATHOLOGICAL COMPLETE RESPONSE | ONCOLOGY | DOSE-DENSE | POSTMENOPAUSAL WOMEN
Journal Article
European Journal of Cancer, ISSN 0959-8049, 10/2018, Volume 102, pp. 40 - 48
Dose-dense administration of chemotherapy and the addition of taxanes to anthracycline-based adjuvant chemotherapy have improved breast cancer survival... 
Biomarker discovery | Efficacy | Chemotherapy | Breast cancer | Dose-dense | Taxane | NODES | METAANALYSIS | PHASE-III | FOLLOW-UP | REGIMENS | WOMEN | THERAPY | ONCOLOGY | Anthracyclines | Cyclophosphamide | Health aspects | Risk factors
Journal Article